Feeling Nature's PAINS: Natural Products, Natural Product Drugs, and Pan Assay Interference Compounds (PAINS).

We have previously reported on classes of compounds that can interfere with bioassays via a number of different mechanisms and termed such compounds Pan Assay INterference compoundS, or PAINS. These compounds were defined on the basis of high-throughput data derived from vendor-supplied synthetics. The question therefore arises whether the concept of PAINS is relevant to compounds of natural origin. Here, it is shown that this is indeed the case, but that the context of the biological readout is an important factor that must be brought into consideration.

[1]  M. Gross,et al.  Balance of beneficial and deleterious health effects of quinones: a case study of the chemical properties of genistein and estrone quinones. , 2009, Journal of the American Chemical Society.

[2]  T. Ishii,et al.  Covalent modification of proteins by green tea polyphenol (-)-epigallocatechin-3-gallate through autoxidation. , 2008, Free radical biology & medicine.

[3]  J. Baell,et al.  A new class of blockers of the voltage-gated potassium channel Kv1.3 via modification of the 4- or 7-position of khellinone. , 2006, Journal of medicinal chemistry.

[4]  John P. Overington,et al.  The promise and peril of chemical probes. , 2015, Nature chemical biology.

[5]  J Willem M Nissink,et al.  Promiscuous 2-aminothiazoles (PrATs): a frequent hitting scaffold. , 2015, Journal of medicinal chemistry.

[6]  Hualiang Jiang,et al.  Structures and mechanism for the design of highly potent glucocorticoids , 2014, Cell Research.

[7]  R. Norton,et al.  Development of Highly Selective Kv1.3-Blocking Peptides Based on the Sea Anemone Peptide ShK , 2015, Marine drugs.

[8]  A. Szallasi,et al.  Medicinal chemistry of the vanilloid (Capsaicin) TRPV1 receptor: current knowledge and future perspectives , 2007 .

[9]  S. Sadeghi,et al.  Spectrophotometric determination of rifampicin through chelate formation and charge transfer complexation in pharmaceutical preparation and biological fluids. , 2006, Chemical & pharmaceutical bulletin.

[10]  Stephen V Frye,et al.  The art of the chemical probe. , 2010, Nature chemical biology.

[11]  M. Lichtman.  A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3. , 2013, Blood cells, molecules & diseases.

[12]  D. Mereles,et al.  Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises? , 2011, International journal of molecular sciences.

[13]  J. Subramony.  Apomorphine in dopaminergic therapy. , 2006, Molecular pharmaceutics.

[14]  B. Blagg,et al.  Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site. , 2006, Current topics in medicinal chemistry.

[15]  Pierre Tufféry,et al.  The FAF-Drugs2 server: a multistep engine to prepare electronic chemical compound collections , 2011, Bioinform..

[16]  H. Reichenbach,et al.  Epothilone A and B—Novel 16-Membered Macrolides with Cytotoxic Activity: Isolation, Crystal Structure, and Conformation in Solution† , 1996 .

[17]  J. Verweij,et al.  Mitomycin C. , 1990, Cancer chemotherapy and biological response modifiers.

[18]  Christian Scheurer,et al.  Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria , 2011, Proceedings of the National Academy of Sciences.

[19]  B. Aggarwal,et al.  Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials , 2012, The AAPS Journal.

[20]  I. McLay,et al.  X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. , 2008, Journal of medicinal chemistry.

[21]  Jonathan B. Baell,et al.  Broad Coverage of Commercially Available Lead-like Screening Space with Fewer than 350, 000 Compounds , 2013, J. Chem. Inf. Model..

[22]  Y. Surh,et al.  Capsaicin induces heme oxygenase-1 expression in HepG2 cells via activation of PI3K-Nrf2 signaling: NAD(P)H:quinone oxidoreductase as a potential target. , 2007, Antioxidants & redox signaling.

[23]  B. Ligon,et al.  Penicillin: its discovery and early development. , 2004, Seminars in pediatric infectious diseases.

[24]  G M Cohen,et al.  Different forms of cell death induced by putative BCL2 inhibitors , 2009, Cell Death and Differentiation.

[25]  Hannu Raunio,et al.  Prodrugs—from Serendipity to Rational Design , 2011, Pharmacological Reviews.

[26]  E. Fox.  Mechanism of action of mitoxantrone , 2004, Neurology.

[27]  R. Schneider-Stock,et al.  Thymoquinone: fifty years of success in the battle against cancer models. , 2014, Drug discovery today.

[28]  Rajarshi Guha,et al.  KNIME Workflow to Assess PAINS Filters in SMARTS Format. Comparison of RDKit and Indigo Cheminformatics Libraries , 2011, Molecular informatics.

[29]  Tina Hernandez-Boussard,et al.  Doxorubicin pathways: pharmacodynamics and adverse effects , 2011, Pharmacogenetics and genomics.

[30]  Olivier Sperandio,et al.  FAF-Drugs3: a web server for compound property calculation and chemical library design , 2015, Nucleic Acids Res..

[31]  S. Jain,et al.  Cyclin-dependent kinase inhibition by flavoalkaloids. , 2012, Mini reviews in medicinal chemistry.

[32]  R. Naik,et al.  An antiinflammatory cum immunomodulatory piperidinylbenzopyranone from dysoxylum binectariferum : isolation, structure and total synthesis , 1988 .

[33]  M. Wani,et al.  Discovery to Clinic a , 1996 .

[34]  Stefano Forli.  Epothilones: From discovery to clinical trials. , 2014, Current topics in medicinal chemistry.

[35]  S. Srivastava,et al.  Reactive intermediates produced from the metabolism of the vanilloid ring of capsaicinoids by p450 enzymes. , 2013, Chemical research in toxicology.

[36]  A. Bode,et al.  The two faces of capsaicin. , 2011, Cancer research.

[37]  G. Rishton,et al.  Natural products as a robust source of new drugs and drug leads: past successes and present day issues. , 2008, The American journal of cardiology.

[38]  N. Russo,et al.  Ab initio calculations on the (1)O2 quenching mechanism by trans-resveratrol. , 2014, Physical chemistry chemical physics : PCCP.

[39]  Céline Douat-Casassus,et al.  Plant polyphenols: chemical properties, biological activities, and synthesis. , 2011, Angewandte Chemie.

[40]  P. Sensi.  History of the development of rifampin. , 1983, Reviews of infectious diseases.

[41]  M. Cooper,et al.  Natural product and natural product derived drugs in clinical trials. , 2014, Natural product reports.

[42]  Jayme L. Dahlin,et al.  PAINS in the Assay: Chemical Mechanisms of Assay Interference and Promiscuous Enzymatic Inhibition Observed during a Sulfhydryl-Scavenging HTS , 2015, Journal of medicinal chemistry.

[43]  John E. Scott,et al.  Discovery of Cercosporamide, a Known Antifungal Natural Product, as a Selective Pkc1 Kinase Inhibitor through High-Throughput Screening , 2004, Eukaryotic Cell.

[44]  Recent progress in the development of sortase A inhibitors as novel anti-bacterial virulence agents , 2015 .

[45]  Wolfgang Guba,et al.  Development of a virtual screening method for identification of "frequent hitters" in compound libraries. , 2002, Journal of medicinal chemistry.

[46]  G. Rishton.  Reactive compounds and in vitro false positives in HTS , 1997 .

[47]  E. Coutinho,et al.  Gossypol: a contraceptive for men. , 2002, Contraception.

[48]  M. A. Tejada,et al.  Tetrodotoxin (TTX) as a Therapeutic Agent for Pain , 2012, Marine drugs.

[49]  E. Toone,et al.  Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries. , 2008, Chemistry & biology.

[50]  A. Holmgren,et al.  A new mechanism of action for the anticancer drug mitomycin C: mechanism-based inhibition of thioredoxin reductase. , 2012, Chemical research in toxicology.

[51]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[52]  U. Hellmann-Blumberg,et al.  Production of hydrogen peroxide and redox cycling can explain how sanguinarine and chelerythrine induce rapid apoptosis. , 2008, Archives of biochemistry and biophysics.

[53]  P. Kovacic.  Mechanism of drug and toxic actions of gossypol: focus on reactive oxygen species and electron transfer. , 2003, Current medicinal chemistry.

[54]  J. Baell,et al.  Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity. , 2004, Journal of medicinal chemistry.

[55]  Robert Mah,et al.  Drug discovery considerations in the development of covalent inhibitors. , 2014, Bioorganic & medicinal chemistry letters.

[56]  S. Sieber,et al.  Electrophilic natural products and their biological targets. , 2012, Natural product reports.

[57]  Mark E Bunnage,et al.  Know your target, know your molecule. , 2015, Nature chemical biology.

[58]  David Julius,et al.  Molecular Basis for Species-Specific Sensitivity to “Hot” Chili Peppers , 2002, Cell.

[59]  T. Shibamoto,et al.  The role of flavor and fragrance chemicals in TRPA1 (transient receptor potential cation channel, member A1) activity associated with allergies , 2015, Allergy, Asthma & Clinical Immunology.

[60]  H. Reichenbach,et al.  Discovery and Development of the Epothilones , 2008, Drugs in R&D.

[61]  P. van Bladeren,et al.  Identification of o‐quinone/quinone methide metabolites of quercetin in a cellular in vitro system , 2002, FEBS letters.

[62]  Jean M. Severin,et al.  Toxicological evaluation of thiol-reactive compounds identified using a la assay to detect reactive molecules by nuclear magnetic resonance. , 2007, Chemical research in toxicology.

[63]  C. Faurant,et al.  From bark to weed: The history of artemisinin , 2011, Parasite.

[64]  P. B. Luis,et al.  Degradation of Curcumin: From Mechanism to Biological Implications. , 2015, Journal of agricultural and food chemistry.

[65]  George Nikolakopoulos,et al.  PAINS: Relevance to Tool Compound Discovery and Fragment-Based Screening , 2013 .

[66]  James Inglese,et al.  Mitigating risk in academic preclinical drug discovery , 2015, Nature Reviews Drug Discovery.

[67]  C. Rudin,et al.  A Phase II Study of AT-101 (Gossypol) in Chemotherapy-Sensitive Recurrent Extensive-Stage Small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[68]  G. Rishton,et al.  Molecular diversity in the context of leadlikeness: compound properties that enable effective biochemical screening. , 2008, Current opinion in chemical biology.

[69]  S. Kaufmann,et al.  How does doxorubicin work? , 2012, eLife.

[70]  Jonathan B. Baell,et al.  Redox-active nuisance screening compounds and their classification , 2011 .

[71]  Stuart Gillies,et al.  Menadione-induced Reactive Oxygen Species Generation via Redox Cycling Promotes Apoptosis of Murine Pancreatic Acinar Cells* , 2006, Journal of Biological Chemistry.

[72]  A. Narayanan,et al.  Chemical motifs that redox cycle and their associated toxicity , 2013 .

[73]  T. Preston,et al.  Safety and toxicological evaluation of a synthetic vitamin K2, menaquinone-7 , 2011, Toxicology mechanisms and methods.

[74]  J. Ulrichová,et al.  Fluorescence of sanguinarine: fundamental characteristics and analysis of interconversion between various forms , 2009, Analytical and bioanalytical chemistry.

[75]  Helgi I. Ingólfsson,et al.  Phytochemicals Perturb Membranes and Promiscuously Alter Protein Function , 2014, ACS chemical biology.

[76]  J. Bolton.  Quinone Methide Bioactivation Pathway: Contribution to Toxicity and/or Cytoprotection? , 2014, Current organic chemistry.

[77]  Martin Pouliot,et al.  Pan Assay Interference Compounds (PAINS) and Other Promiscuous Compounds in Antifungal Research. , 2016, Journal of medicinal chemistry.

[78]  J. Baell.  Observations on screening-based research and some concerning trends in the literature. , 2010, Future medicinal chemistry.

[79]  G. S. Walker,et al.  Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors. , 2014, Journal of medicinal chemistry.

[80]  Andreas Hofmann,et al.  A practical Java tool for small-molecule compound appraisal , 2015, Journal of Cheminformatics.

[81]  D. Selkoe,et al.  Dopamine covalently modifies and functionally inactivates parkin , 2005, Nature Medicine.

[82]  Jonathan B Baell,et al.  Screening-based translation of public research encounters painful problems. , 2015, ACS medicinal chemistry letters.

[83]  N. Palepu,et al.  Preformulation studies to aid in the development of a ready-to-use injectable solution of the antitumor agent, topotecan , 1996 .

[84]  G. Rishton.  Nonleadlikeness and leadlikeness in biochemical screening. , 2003, Drug discovery today.

[85]  C. Proud,et al.  Targeting Mnks for Cancer Therapy , 2012, Oncotarget.

[86]  David J Newman,et al.  Natural products as sources of new drugs over the 30 years from 1981 to 2010. , 2012, Journal of natural products.

[87]  G. Ferland.  The Discovery of Vitamin K and Its Clinical Applications , 2012, Annals of Nutrition and Metabolism.

[88]  M. Scheulen,et al.  Covalent protein binding of reactive adriamycin metabolites in rat liver and rat heart microsomes , 2004, Journal of Cancer Research and Clinical Oncology.

[89]  V. Dembitsky.  Astonishing diversity of natural surfactants: 6. Biologically active marine and terrestrial alkaloid glycosides , 2005, Lipids.

[90]  Bin Liu,et al.  Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum , 2015, Nature Communications.

[91]  L. Pearl,et al.  In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. , 2007, Cancer research.

[92]  Jonathan Bisson,et al.  Can Invalid Bioactives Undermine Natural Product-Based Drug Discovery? , 2015, Journal of medicinal chemistry.

[93]  J. Clader.  The discovery of ezetimibe: a view from outside the receptor. , 2004, Journal of medicinal chemistry.

[94]  Yun-Jin Jung,et al.  Curcumin is an inhibitor of p300 histone acetylatransferase. , 2006, Medicinal chemistry (Shariqah (United Arab Emirates)).

[95]  C. Scott,et al.  The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. , 2006, Cancer cell.

[96]  J. Baell,et al.  Chemistry: Chemical con artists foil drug discovery , 2014, Nature.

[97]  C. Crews,et al.  From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes. , 2013, Natural product reports.